Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LepVax in Healthy Adults in Leprosy Endemic Areas
NCT06627257Phase 1Not yet recruiting
- Sponsor
- Immunobiological Technology Institute
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LepVax in leprosy (HD) (3 arms), sponsored by Immunobiological Technology Institute. Primary endpoints: Number of participants with local and systemic reactions, Number of participants experiencing unsolicited adverse events and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
LepVax
03
Conditions
leprosy (HD)
Beyond the preview
Go deeper on NCT06627257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627257.